Arcellx

News

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.